Leerink sees about $440 million peptide revenue chance for Hims & Hers
Tue 11:12
BUZZ-Leerink sees about $440 million peptide revenue chance for Hims & Hers ** Leerink Partners stimates a ~$2.2 bln telehealth peptide market, translating to ~$440 mln revenue and about $70 mln in core profit opportunity for Hims & Hers HIMS.N
** Brokerage says narrower prescribing could halve the opportunity to ~$1.1 bln market, ~$220 mln revenue and about $25 mln in core profit
** Says opportunity hinges on July FDA advisory panel weighing use of 7 peptides in compounding
** Notes commercialization unlikely before end-2026, with meaningful upside seen from 2027 and beyond
** Flags safety, efficacy and prescribing limits as key risks to uptake
** Leerink rates stock “market perform”, sees near-term focus on GLP-1 profitability
** Including session's move, stock down ~7% YTD
(Reporting by Sahil Pandey in Bengaluru)